

Hemispherian AS



Gaustadalleen 23a
P.O. Box 114 Blindern
0314 Oslo
+47 406 03 455

Hemispherian launches its synthetic biology operations

February 05, 2018

Hemispherian has negotiated with ShareLab to use their facilities to produce GenomeStrands. GenomeStrands are long single-stranded DNA substrates that can be used to promote precise gene editing in combination with gene editing tools including CRISPR/Cas9.

Single-stranded DNA is the preferred substrate for precise gene repair followed by CRISPR/Cas9 cleavage. An important factor precise gene repair is template length, longer single-stranded DNA fragments are more efficiently incorporated into the genome. Using present technologies, longer single-stranded DNA fragments are difficult and prohibitively expensive to synthesize. GenomeStrands are single-stranded DNA substrates that are produced using our proprietary technology. GenomeStrands are longer, made at a higher-yield, and can be made at a fraction of the cost of present solutions. GenomeStrands allows our customers to conduct more experiments at higher efficiencies, while reducing our customers' cost. Due to the involvement of CRISPR/Cas9, demand for these types of DNA substrates is large; however, the cost of competing solutions is excessive, providing a large market for our cheaper and better solution. GenomeStrands solves the most expensive and difficult aspect of CRISPR/Cas9 precise genome engineering, a market that is growing at almost 15% a year and is expected to represent a \$3.61 billion market by 2021. A modest market penetration of 10-20% would represent significant gains in the Norwegian biotech industry and the economy as a whole.



Pierre Chymkowitz, Chief Science Officer and Adam Robertson, Chief of Synthetic Biology Operations with Hemispherian starting work on GenomeStrands at ShareLab.

GenomeStrands will be available at the end of Q1, 2018. For more information please contact: info@hemispherian.com.